Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 January 2007Website:
http://www.sonomapharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:57:40 GMTDividend
Analysts recommendations
Institutional Ownership
SNOA Latest News
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Revenues increased 14% in Q4 2024 compared to Q4 2023 Gross profit margin improved 3% in FY 2024 compared to FY 2023 Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023 BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024. "We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results.
Sonoma Pharmaceuticals shares jumped 44% on Friday after the company unveiled a product that could replace IV bags for some surgeries.
What type of business is Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
What sector is Sonoma Pharmaceuticals in?
Sonoma Pharmaceuticals is in the Healthcare sector
What industry is Sonoma Pharmaceuticals in?
Sonoma Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Sonoma Pharmaceuticals from?
Sonoma Pharmaceuticals is headquartered in United States
When did Sonoma Pharmaceuticals go public?
Sonoma Pharmaceuticals initial public offering (IPO) was on 25 January 2007
What is Sonoma Pharmaceuticals website?
https://www.sonomapharma.com
Is Sonoma Pharmaceuticals in the S&P 500?
No, Sonoma Pharmaceuticals is not included in the S&P 500 index
Is Sonoma Pharmaceuticals in the NASDAQ 100?
No, Sonoma Pharmaceuticals is not included in the NASDAQ 100 index
Is Sonoma Pharmaceuticals in the Dow Jones?
No, Sonoma Pharmaceuticals is not included in the Dow Jones index
When does Sonoma Pharmaceuticals report earnings?
The next expected earnings date for Sonoma Pharmaceuticals is 09 August 2024